Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors

Open access
Jones, Steven JM, Laskin, Janessa, Li, Yvonne Y, Griffith, Obi L, An, Jianghong, Bilenky, Mikhail, Butterfield, Yaron S, Cezard, Timothee, Chuah, Eric, Corbett, Richard, Fejes, Anthony P, Griffith, Malachi, Yee, John, Martin, Montgomery, Mayo, Michael, Melnyk, Nataliya, Morin, Ryan D, Pugh, Trevor J, Severson, Tesa, Shah, Sohrab P, Sutcliffe, Margaret, Tam, Angela, Terry, Jefferson, Thiessen, Nina, Thomson, Thomas, Varhol, Richard, Zeng, Thomas, Zhao, Yongjun, Moore, Richard A, Huntsman, David G, Birol, Inanc, Hirst, Martin, Holt, Robert A, Marra, Marco A·2010·Genome Biology

Abstract

Background: Adenocarcinomas of the tongue are rare and represent the minority (20 to 25%) of salivary gland tumors affecting the tongue. We investigated the utility of massively parallel sequencing to characterize an adenocarcinoma of the tongue, before and after treatment. Results: In the pre-treatment tumor we identified 7,629 genes within regions of copy number gain. There were 1,078 genes that exhibited increased expression relative to the blood and unrelated tumors and four genes contained somatic protein-coding mutations. Our analysis suggested the tumor cells were driven by the RET oncogene. Genes whose protein products are targeted by the RET inhibitors sunitinib and sorafenib correlated with being amplified and or highly expressed. Consistent with our observations, administration of sunitinib was associated with stable disease lasting 4 months, after which the lung lesions began to grow. Administration of sorafenib and sulindac provided disease stabilization for an additional 3 months after which the cancer progressed and new lesions appeared. A recurring metastasis possessed 7,288 genes within copy number amplicons, 385 genes exhibiting increased expression relative to other tumors and 9 new somatic protein coding mutations. The observed mutations and amplifications were consistent with therapeutic resistance arising through activation of the MAPK and AKT pathways. Conclusions: We conclude that complete genomic characterization of a rare tumor has the potential to aid in clinical decision making and identifying therapeutic approaches where no established treatment protocols exist. These results also provide direct in vivo genomic evidence for mutational evolution within a tumor under drug selection and potential mechanisms of drug resistance accrual.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/gb-2010-11-8-r82

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 175

Metadata

Authors
Jones, S. J., Laskin, J., Li, Y. Y., Griffith, O. L., An, J., Bilenky, M., Butterfield, Y. S., Cezard, T., Chuah, E., Corbett, R., Fejes, A. P., Griffith, M., Yee, J., Martin, M., Mayo, M., Melnyk, N., Morin, R. D., Pugh, T. J., Severson, T., Shah, S. P., Sutcliffe, M., Tam, A., Terry, J., Thiessen, N., Thomson, T., Varhol, R., Zeng, T., Zhao, Y., Moore, R. A., Huntsman, D. G., Birol, I., Hirst, M., Holt, R. A., & Marra, M. A.
Venue
Genome Biology
Published
2010-08-09
Volume
11
Issue
8
Pages
R82-R82
ISSN
  • 1465-6906 (ISSN-L)
  • 1474-760X
OpenAlex
W2104108814
Cited by
175
References
8
FWCI
6.41
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. https://app.cochat.ai/papers/10.1186/gb-2010-11-8-r82
The paper
Jones, S. J., Laskin, J., Li, Y. Y., Griffith, O. L., An, J., Bilenky, M., Butterfield, Y. S., Cezard, T., Chuah, E., Corbett, R., Fejes, A. P., Griffith, M., Yee, J., Martin, M., Mayo, M., Melnyk, N., Morin, R. D., Pugh, T. J., Severson, T., . . . Marra, M. A. (2010). Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biology. https://doi.org/10.1186/gb-2010-11-8-r82

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.